Torrent Pharma, Eli Lilly ink pact to boost Baricitinib production in India
Advertisement
Ahmedabad: Following in the footsteps of Sun Pharma, Cipla, and Lupin in signing a voluntary licencing agreement with Eli Lilly to accelerate the production of Baricitinib for the treatment of COVID-19 patients in India, now Torrent Pharmaceuticals has signed a royalty free, non-exclusive voluntary licencing agreement with Eli Lilly to boost the production of Baricitinib.
Under the agreement, Lilly has provided the license to manufacture and distribute baricitinib to Torrent for India along with Lilly's other license partners.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.